Noveris Health Sciences Inc., formerly Mydecine Innovations Group Inc., is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with scientific and regulatory expertise.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	5.56M 4.03M 3.46M 3.26M 2.97M 383M 5.58M 38.67M 14.94M 195M 15.12M 14.79M 618M	P/E 2024	-0.19x	P/E 2025	0.13x
Enterprise Value	15.14M 10.96M 9.43M 8.88M 8.09M 1.04B 15.2M 105M 40.67M 531M 41.14M 40.25M 1.68B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.95%	Yield 2024 *	-	Yield 2025	-

09-01	Noveris Health Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Noveris Health Sciences to Raise C$500,000 From a Private Placement of Convertible Debentures	MT
08-19	Noveris Health Sciences Inc. announced that it expects to receive CAD 0.5 million in funding	CI
08-18	Noveris Health Sciences Receives Uspto Notice of Allowance for Aza-Substituted Psilocin Analogs and Signs Work Order with Api	CI
06-12	Noveris Health Sciences Appoints Nathan Mison as Chair of Advisory Board	CI
05-29	Noveris Health Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-01	Noveris Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Noveris Health Sciences Inc. Auditor Raises 'Going Concern' Doubt	CI
04-28	Noveris Health Sciences Inc. signed a term sheet to acquire 49% stake in ELL Stem Cells for $1 million.	CI
03-17	Noveris Health Sciences Inc. announced that it has received CAD 2.310012 million in funding	CI
03-12	Noveris Health Sciences Inc. announced that it expects to receive CAD 2.5 million in funding	CI
03-10	Noveris Health Sciences Inc. Announces Board Changes	CI
03-10	Noveris Health Sciences Inc. Announces CEO Changes	CI

09-09	Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting	NE
08-20	Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000	NE
08-18	Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API	NE
08-06	Noveris Health Sciences Inc. Unaware of Any Material Change	NE
07-30	Noveris Health Sciences Joins BioAlberta	NE

Manager	Title	Age	Since
Jason Birmingham CEO	Chief Executive Officer	53	09/03/2026
John Ross DFI	Director of Finance/CFO	67	15/09/2022

Director	Title	Age	Since
Michael Callas BRD	Director/Board Member	-	20/03/2025
Peter Field BRD	Director/Board Member	-	17/03/2025
Jason Birmingham BRD	Director/Board Member	53	09/03/2026

New Age Farm Inc Share Price Canadian Securities Exchange

Stocks

CA64157D1087

Biotechnology & Medical Research

Valuation : New Age Farm Inc

Latest news : New Age Farm Inc

Press Releases : New Age Farm Inc

Quotes and Performance

Managers and Directors : New Age Farm Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEW AGE FARM INC	-8.33%	+33.33%	-	-	4.03M
LONZA GROUP AG	+0.59%	-6.94%	-2.69%	+11.17%	46.38B
REVOLUTION MEDICINES, INC.	-1.12%	-3.16%	+404.82%	+521.24%	44.51B
IQVIA HOLDINGS INC.	-1.30%	-6.53%	+38.08%	+17.91%	42.3B
BEONE MEDICINES AG	-2.38%	-5.41%	+9.27%	+63.95%	39.91B
CELLTRION, INC.	0.00%	-1.72%	+13.42%	+42.33%	32.79B
ASCENDIS PHARMA A/S	-0.40%	-4.06%	-	-	17.13B
MEDPACE HOLDINGS, INC.	-0.36%	-1.53%	+22.58%	+109.17%	16.36B
EUROFINS SCIENTIFIC SE	+0.48%	-2.94%	+13.28%	+31.60%	14.31B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.29%	-7.10%	+77.81%	+36.50%	13.29B
Average	-1.43%	-2.88%	+72.07%	+104.23%	29.66B
Weighted average by Cap.	-0.73%	-3.04%	+87.69%	+124.64%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.28M -1.96M -1.85M -1.68M -217M -3.16M -21.91M -8.47M -111M -8.57M -8.38M -350M	2.92M 2.11M 1.82M 1.71M 1.56M 201M 2.93M 20.31M 7.85M 103M 7.94M 7.77M 325M
Net Debt	6.87M 4.98M 4.28M 4.03M 3.67M 474M 6.9M 47.79M 18.47M 241M 18.69M 18.28M 764M	9.57M 6.93M 5.96M 5.62M 5.12M 659M 9.61M 66.55M 25.72M 336M 26.02M 25.46M 1.06B